大葉大學圖書館 |

Target validation in drug discovery[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615/.19
書名/作者:	Target validation in drug discovery/ editors, Brian W. Metcalf and Susan Dillon.
其他作者:	Metcalf, Brian W.
出版者:	Amsterdam ; : Academic Press,, c2007.
面頁冊數:	xii, 279 p. : : ill. ;; 27 cm.
標題:	Drug development.
標題:	Drugs - Testing.
標題:	High throughput screening (Drug development)
標題:	Drug Design.
標題:	Drug Delivery Systems.
標題:	Technology, Pharmaceutical.
標題:	M�edicaments - D�eveloppement.
標題:	M�edicaments - Essais cliniques.
標題:	Criblage �a haut d�ebit (D�eveloppement des m�edicaments)
ISBN:	9780123693938
ISBN:	0123693934
書目註:	Includes bibliographical references and index.
內容註:	Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.
摘要、提要註:	This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
電子資源:	An electronic book accessible through the World Wide Web; click for information

Target validation in drug discovery[electronic resource] /
Target validation in drug discovery[electronic resource] /editors, Brian W. Metcalf and Susan Dillon. - Amsterdam ;Academic Press,c2007. - xii, 279 p. :ill. ;27 cm.

Includes bibliographical references and index.

Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2007.

Mode of access: World Wide Web.

ISBN: 9780123693938

Source: 113098:113186Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

339189
Drug development.
Index Terms--Genre/Form:

336502
Electronic books.

LC Class. No.: RM301.63 / .T36 2007eb

Dewey Class. No.: 615/.19

National Library of Medicine Call No.: 2006 N-124

Target validation in drug discovery[electronic resource] /
LDR:02330cam 2200349Ia 4500 001 347575
003 OCoLC
005 20110615082928.0
006 m d
007 cr cn|||||||||
008 111130s2007 enka ob 001 0 eng d
020 $a 9780123693938
020 $a 0123693934
029 1 $a NZ1 $b 11778208
035 $a (OCoLC)162130366
035 $a ocn162130366
037 $a 113098:113186 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $c OPELS $d OCLCG
049 $a TEFA
050 1 4 $a RM301.63 $b .T36 2007eb
060 1 4 $a 2006 N-124
060 1 4 $a QV 744 $b T185 2007
082 0 4 $a 615/.19 $2 22
245 0 0 $a Target validation in drug discovery $h [electronic resource] / $c editors, Brian W. Metcalf and Susan Dillon.
260 $a Amsterdam ; $a Boston : $b Academic Press, $c c2007.
300 $a xii, 279 p. : $b ill. ; $c 27 cm.
504 $a Includes bibliographical references and index.
505 0 $a Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.
520 $a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
533 $a Electronic reproduction. $b Amsterdam : $c Elsevier Science & Technology, $d 2007. $n Mode of access: World Wide Web. $n System requirements: Web browser. $n Title from title screen (viewed on July 25, 2007). $n Access may be restricted to users at subscribing institutions.
650 0 $a Drug development. $3 339189
650 0 $a Drugs $x Testing. $3 431364
650 0 $a High throughput screening (Drug development) $3 431365
650 1 2 $a Drug Design. $3 402272
650 2 2 $a Drug Delivery Systems. $3 383420
650 2 2 $a Technology, Pharmaceutical. $3 431366
650 6 $a M�edicaments $x D�eveloppement. $3 431367
650 6 $a M�edicaments $x Essais cliniques. $3 431368
650 6 $a Criblage �a haut d�ebit (D�eveloppement des m�edicaments) $3 431369
655 7 $a Electronic books. $2 local $3 336502
700 1 $a Metcalf, Brian W. $3 431362
700 1 $a Dillon, Susan, $d 1952- $3 431363
710 2 $a ScienceDirect (Online service) $3 365609
776 1 $c Original $z 0123693934 $z 9780123693938 $z 9780123693938 $w (DLC) 2006049868 $w (OCoLC)70823305
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780123693938 $z An electronic book accessible through the World Wide Web; click for information
994 $a C0 $b TEF